Sugi Predict

Sugi Predict / Compounds / SCHEMBL422013

SCHEMBL422013

SCHEMBL422013

O=c1[nH]c2sccc2c2ccccc12

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TNKS2 Q9H2K2 8/20 1.00
▸ PARP1 P09874 8/20 1.00
▸ PARP15 Q460N3 6/20 1.00
▸ TNKS O95271 2/20 1.00
▸ PARP2 Q9UGN5 5/20 0.62
▸ PARP10 Q53GL7 4/20 0.62
▸ PARP14 Q460N5 1/20 0.57
▸ MEN1 O00255 2/20 0.56
▸ ALDH1A1 P00352 2/20 0.56
▸ KMT2A Q03164 2/20 0.56
▸ MAPK1 P28482 1/20 0.56
▸ KDM4E B2RXH2 1/20 0.50
▸ LMNA P02545 1/20 0.50
▸ CYP1A2 P05177 1/20 0.50
▸ GPR3 P46089 1/20 0.50
▸ BLM P54132 1/20 0.50
▸ PMP22 Q01453 1/20 0.50
▸ HSD17B10 Q99714 1/20 0.50
▸ DAO P14920 1/20 0.48
▸ FGFR1 P11362 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29478203 1.00 TNKS2 (1.00) TNKS2PARP1PARP15TNKSPARP2
SCHEMBL1549733 0.77 TNKS2 (0.62) TNKS2PARP1PARP15TNKSPARP2
SCHEMBL1549073 0.77 TNKS2 (0.67) TNKS2PARP1PARP15TNKSPARP2
SCHEMBL16472188 0.77 TNKS2 (0.67) TNKS2PARP1PARP15TNKSPARP2
SCHEMBL1549859 0.75 TNKS2 (0.60) TNKS2PARP1PARP15TNKSPARP2
SCHEMBL16472184 0.75 TNKS2 (0.60) TNKS2PARP1PARP15TNKSPARP2
SCHEMBL1549492 0.75 TNKS2 (0.60) TNKS2PARP1PARP15TNKSPARP2
SCHEMBL2463714 0.75 PARP1 (0.60) TNKS2PARP1PARP15TNKSPARP2
SCHEMBL993597 0.75 KMT2A (0.66) TNKS2PARP1PARP15TNKSPARP2
SCHEMBL5430913 0.75 PARP15 (0.60) TNKS2PARP1PARP15TNKSPARP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10709724-B2 Methods of treating mitochondrial dysfunction ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL) (CH) 2020-07-14 — — US claimed
US-20140303201-A1 CANCER THERAPY COHEN-ARMON MALKA (IL) 2014-10-09 — — US claimed
EP-2131651-B1 TOPICAL CORNEAL ANALGESIA USING NEUROTENSIN RECEPTOR AGONISTS SARENTIS THERAPEUTICS INC (US) 2013-05-22 — — EP claimed
EP-2207548-B1 BREAST CANCER THERAPY COHEN-ARMON MALKA (IL) 2013-05-22 — — EP claimed
US-20120022026-A1 METHOD OF TREATING CANCER ERASMUS UNIVERSITY MEDICAL CENTER ROTTERDAM (NL) 2012-01-26 — — US claimed
EP-2387403-A1 METHOD OF TREATING CANCER Academisch Medisch Centrum bij de Universiteit van Amsterdam (NL) 2011-11-23 — — EP claimed
US-20110253692-A1 Electrical heater for vehicle windshields and windows SCHAUBLE RICHARD EGON 2011-10-20 — — US claimed
US-20100284964-A1 CANCER THERAPY RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) 2010-11-11 — — US claimed
US-7825129-B2 Thieno[2,3-c] isoquinolines for use as inhibitors of PARP PELLICCIARI ROBERTO 2010-11-02 — — US claimed
WO-2010082821-A1 METHOD OF TREATING CANCER ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM (NL) 2010-07-22 — — WO claimed
EP-1464646-B1 Thieno(2,3-C) Isoquinolines for use as inhibitors of Parp PELLICCIARI ROBERTO (IT) 2009-09-30 — — EP claimed
US-20060094746-A1 Thieno[2,3-c] isoquinolines for use as inhibitors of PARP PELLICCIARI ROBERTO 2006-05-04 — — US claimed
US-6989388-B2 Thieno[2,3-c]iosquinolines for use as inhibitors of PARP Pellicciari, Roberto (IT) 2006-01-24 — — US claimed
EP-1464646-A1 Thieno(2,3-C) Isoquinolines for use as inhibitors of Parp SMITHKLINE BEECHAM PLC (GB) 2004-10-06 — — EP claimed
US-20040082789-A1 Thieno[2,3-c]iosquinolines for use as inhibitors of parp MORONI, FLAVIO (IT) 2004-04-29 — — US claimed
US-20250161247-A1 METHOD FOR TREATING BREAST CANCERS AND PARP RESISTANT BREAST CANCERS LANTERN PHARMA INC. (US) 2025-05-22 — — US disclosed
US-20240299322-A1 TREATING CANCERS WITH COMBINATIONS OF PARP INHIBITOR AND ACYLFULVENES LANTERN PHARMA INC. (US) 2024-09-12 — — US disclosed
US-6989388-B2 Thieno[2,3-c]iosquinolines for use as inhibitors of PARP Pellicciari, Roberto (IT) 2006-01-24 — — US disclosed
EP-1464646-A1 Thieno(2,3-C) Isoquinolines for use as inhibitors of Parp SMITHKLINE BEECHAM PLC (GB) 2004-10-06 — — EP disclosed
US-20040082789-A1 Thieno[2,3-c]iosquinolines for use as inhibitors of parp MORONI, FLAVIO (IT) 2004-04-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250161247-A1 METHOD FOR TREATING BREAST CANCERS AND PARP RESISTANT BREAST CANCERS PARP1, PARP2, PARP3 TNKS2 18/4885PARP1 1/4885PARP15 9/4885
US-20140303201-A1 CANCER THERAPY TP53, EGFR, CD44 TNKS2 1009/4885PARP1 499/4885PARP15 564/4885
US-20240299322-A1 TREATING CANCERS WITH COMBINATIONS OF PARP INHIBITOR AND ACYLFULVENES PARP1, PARP2, PARP11 TNKS2 15/4885PARP1 1/4885PARP15 13/4885
US-20100284964-A1 CANCER THERAPY TP53, EGFR, CD44 TNKS2 1009/4885PARP1 499/4885PARP15 564/4885
US-20040082789-A1 Thieno[2,3-c]iosquinolines for use as inhibitors of parp PARP1, PARP2, PARP12 TNKS2 17/4885PARP1 1/4885PARP15 6/4885
US-20060094746-A1 Thieno[2,3-c] isoquinolines for use as inhibitors of PARP PARP1, PARP2, PARP3 TNKS2 16/4885PARP1 1/4885PARP15 7/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.